https://www.selleckchem.com/pr....oducts/Temsirolimus.
OBJECTIVES To evaluate initial combination therapy with ambrisentan plus tadalafil (COM compared with monotherapy of either agent (MONO), and the utility of baseline characteristics and risk stratification in predicting outcomes, in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and the systemic sclerosis (SSc)-pulmonary arterial hypertension (PAH) subpopulation. METHODS This post hoc analysis of the Ambrisentan and Tadalafil in Patients with Pulmonary Arterial Hypertension (AMBITION)
Like
Comment
Share
